Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 12/20 | 0.56 |
| ▸ | HTR2B | P41595 | 3/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.46 |
| ▸ | YTHDC1 | Q96MU7 | 3/20 | 0.44 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19807554 | 0.86 | HTR2B (0.43) | ADORA3HTR2BHTR2CADORA1ADORA2A | |
| SCHEMBL21710773 | 0.84 | ADORA3 (0.54) | ADORA3HTR2BHTR2CADORA1ADORA2A | |
| SCHEMBL21710871 | 0.80 | ADORA3 (0.64) | ADORA3ADORA1ADORA2A | |
| SCHEMBL21710750 | 0.76 | ADORA3 (0.52) | ADORA3ADORA1ADORA2A | |
| SCHEMBL24220489 | 0.75 | ADORA3 (0.63) | ADORA3HTR2BADORA1ADORA2A | |
| SCHEMBL22933030 | 0.73 | P2RY1 (0.44) | ADORA3HTR2BHTR2CADORA1ADORA2A | |
| SCHEMBL22937442 | 0.73 | P2RY1 (0.44) | ADORA3HTR2BHTR2CADORA1ADORA2A | |
| SCHEMBL26934922 | 0.73 | P2RY1 (0.44) | ADORA3HTR2BHTR2CADORA1ADORA2A | |
| SCHEMBL19464934 | 0.72 | HTR2B (1.00) | ADORA3HTR2BHTR2CADORA1ADORA2A | |
| SCHEMBL19464867 | 0.72 | HTR2B (1.00) | ADORA3HTR2BHTR2CADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10265338-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180021363-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10265338-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885HTR2B 1044/4885HTR2C 1443/4885 |
| US-20180021363-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885HTR2B 1044/4885HTR2C 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.